IPATF - ImmunoPrecise launches preclinical studies for COVID-19 vaccine

ImmunoPrecise Antibodies (IPATF) and LiteVax have initiated preclinical vaccine trials against SARS-CoV-2. Vaccine design was based on sets of data obtained during the analysis of IPA's SARS-CoV-2 therapeutic programs, and based on this, the company has designed SARS-CoV-2 spike protein variant vaccine candidates combined with synthetic carbohydrate derivatives, designed to act as a vaccine adjuvant.The collaborative study is ongoing in Spain, to assess the safety and tolerability of a single-low-dose of vaccine formulations. Additionally, ImmunoPrecise and LiteVax are initiating relevant ex vivo assays.Study results will be compiled by November and allowing prioritization of subsets of ideal vaccine candidates for further development.

For further details see:

ImmunoPrecise launches preclinical studies for COVID-19 vaccine